The ABI2 antibody is a research tool designed to detect and quantify the Abelson Interactor 2 (ABI2) protein, a regulator of actin cytoskeleton dynamics critical for cell motility, adhesion, and neuronal morphogenesis . ABI2 functions as part of the WAVE complex, enabling Arp2/3-mediated actin polymerization essential for lamellipodia formation and dendritic spine specification . Dysregulation of ABI2 is implicated in cancers, neurological disorders, and drug resistance .
Western Blot (WB): Optimal dilution ranges from 1:2,000 to 1:6,000 . Validated in cell lines (HEK-293, HeLa, SH-SY5Y) and tissues (brain, testis) .
Immunohistochemistry (IHC): Dilution 1:20–1:200; antigen retrieval recommended using citrate (pH 6.0) or TE buffer (pH 9.0) .
Functional Studies: Used to investigate ABI2’s role in cancer stem cell maintenance, metastasis, and drug resistance .
Hepatocellular Carcinoma (HCC): ABI2 overexpression correlates with tumor size, pathological grade, and poor survival. Knockdown suppresses stemness (CD24+/CD133+/CD326+ populations) and sorafenib resistance via MEOX2/KLF4-NANOG axis .
Triple-Negative Breast Cancer (TNBC): Low ABI2 expression promotes metastasis via PI3K/Akt signaling. CBLC E3 ligase mediates ABI2 ubiquitination and degradation .
Prostate Cancer: PIM1 kinase stabilizes ABI2 under hypoxia, enhancing WAVE complex activity and invasiveness .
ABI2 deficiency in mice causes dendritic spine abnormalities, impaired neuronal migration, and memory deficits .
Actin Regulation: ABI2 recruits MEOX2 to activate KLF4 and NANOG transcription, driving cytoskeletal remodeling .
Drug Resistance: CRISPR screening identifies ABI2 as a key mediator of Temozolomide resistance .
ABI2 antibodies are pivotal for elucidating its role in cytoskeletal dynamics and therapeutic targeting. Ongoing studies focus on: